• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肌苷三磷酸酶基因变异对慢性丙型肝炎合并 HIV/丙型肝炎病毒感染患者接受治疗后贫血风险的影响。

Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C.

机构信息

Infectious Diseases Department, Hospital Carlos III, Madrid, Spain.

出版信息

Clin Infect Dis. 2011 Dec;53(12):1291-5. doi: 10.1093/cid/cir665. Epub 2011 Oct 25.

DOI:10.1093/cid/cir665
PMID:22028438
Abstract

The role of rs1127354/rs7270101 alleles at the inosine triphosphatase (ITPA) gene on ribavirin-induced anemia was assessed in 74 patients with hepatitis C virus and human immunodeficiency virus coinfection. Anemia developed in 80% of patients with normal ITPA activity compared with 33% of those with reduced ITPA activity. In contrast, ITPA variants did not influence sustained virological response.

摘要

rs1127354/rs7270101 等位基因在肌苷三磷酸酶（ITPA）基因对利巴韦林诱导的贫血的作用在 74 例丙型肝炎病毒和人类免疫缺陷病毒合并感染患者中进行了评估。与 ITPA 活性降低的患者相比，正常 ITPA 活性的患者中有 80%发生贫血，而 ITPA 活性降低的患者中有 33%发生贫血。相比之下，ITPA 变异并未影响持续病毒学应答。

相似文献

1
Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C.肌苷三磷酸酶基因变异对慢性丙型肝炎合并 HIV/丙型肝炎病毒感染患者接受治疗后贫血风险的影响。
Clin Infect Dis. 2011 Dec;53(12):1291-5. doi: 10.1093/cid/cir665. Epub 2011 Oct 25.
2
Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients.ITPA 多态性 rs6051702/rs1127354 而非 rs7270101/rs1127354 可作为预测慢性丙型肝炎患者接受利巴韦林治疗后贫血的指标。
Antiviral Res. 2013 Oct;100(1):114-9. doi: 10.1016/j.antiviral.2013.07.021. Epub 2013 Aug 8.
3
ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV.ITPA 基因多态性显著影响 HIV 和 HCV 共感染患者的血红蛋白下降和治疗结局。
J Med Virol. 2012 Jul;84(7):1106-14. doi: 10.1002/jmv.23302.
4
Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy.ITPA基因多态性对预测接受索磷布韦-利巴韦林治疗的丙型肝炎病毒感染患者贫血及治疗结局的影响
BMC Infect Dis. 2024 Mar 11;24(1):301. doi: 10.1186/s12879-024-09188-1.
5
Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.ITPA 基因多态性与 HIV/丙型肝炎病毒 (HCV) 合并感染患者接受 HCV 联合治疗后发生利巴韦林诱导性贫血的风险之间的关联。
Antimicrob Agents Chemother. 2012 Jun;56(6):2987-93. doi: 10.1128/AAC.06473-11. Epub 2012 Mar 19.
6
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes.ITPA 基因变异可预防所有 HCV 基因型 HIV/HCV 合并感染患者的利巴韦林诱导溶血性贫血。
J Infect Dis. 2012 Feb 1;205(3):376-83. doi: 10.1093/infdis/jir754. Epub 2011 Dec 9.
7
Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy.肌苷三磷酸酶缺乏有助于预测慢性丙型肝炎治疗中的贫血、贫血管理和反应。
J Viral Hepat. 2013 Dec;20(12):858-66. doi: 10.1111/jvh.12113. Epub 2013 Jun 24.
8
ITPA gene polymorphism (94C>A) effects on ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C.ITPA 基因多态性（94C>A）对埃及慢性丙型肝炎患者治疗期间利巴韦林诱导性贫血的影响。
J Med Virol. 2017 Oct;89(10):1823-1829. doi: 10.1002/jmv.24844. Epub 2017 May 29.
9
Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy.肌苷三磷酸酶多态性与索磷布韦和利巴韦林治疗期间血红蛋白浓度降低及利巴韦林剂量减少之间的相关性。
J Gastroenterol Hepatol. 2017 Aug;32(8):1495-1502. doi: 10.1111/jgh.13743.
10
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.肌苷三磷酸酶基因突变可预防 HCV2/3 抗病毒治疗期间的贫血，但不会减少 RBV 的剂量减少或增加 SVR。
Hepatology. 2011 Feb;53(2):389-95. doi: 10.1002/hep.24068. Epub 2011 Jan 10.

引用本文的文献

1
Is Ribavirin Teratogenic in Humans? No Evidence So Far.利巴韦林对人类有致畸性吗？目前尚无证据。
Drug Saf. 2017 Dec;40(12):1163-1165. doi: 10.1007/s40264-017-0597-z.
2
Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis.利巴韦林治疗的丙型肝炎病毒感染患者中ITPA基因多态性与溶血性贫血的关系：一项荟萃分析
J Transl Med. 2015 Oct 6;13:320. doi: 10.1186/s12967-015-0682-y.
3
Pharmacogenomics of antimicrobial agents.抗菌药物的药物基因组学
Pharmacogenomics. 2014;15(15):1903-30. doi: 10.2217/pgs.14.147.
4
Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants.HCV-HIV 共感染患者 HCV 治疗疗效和安全性的药物遗传学：与 IL28B 和 SOCS3 基因变异的显著关联。
PLoS One. 2012;7(11):e47725. doi: 10.1371/journal.pone.0047725. Epub 2012 Nov 2.
5
Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy.ITPA 基因多态性与 HIV/丙型肝炎病毒 (HCV) 合并感染患者接受 HCV 联合治疗后发生利巴韦林诱导性贫血的风险之间的关联。
Antimicrob Agents Chemother. 2012 Jun;56(6):2987-93. doi: 10.1128/AAC.06473-11. Epub 2012 Mar 19.